Leukocyte Adhesion Deficiency Follow-up

  • Author: Stephen J Nervi, MD; Chief Editor: Harumi Jyonouchi, MD   more...
 
Updated: Apr 2, 2012
 

Further Inpatient Care

  • Leukocyte adhesion deficiency type I (LAD I) is often associated with life-threatening infections requiring intensive care. Coordinating medical management between immunologists, infectious disease specialists, pulmonologists, and surgical specialists is challenging.
  • Excellent laboratory and radiology support mandates hospitalization in tertiary children's medical centers.
Next

Further Outpatient Care

  • Scrupulous follow-up of infections is necessary for patients with leukocyte adhesion deficiency.
  • As noted above, outpatient management of infections has become customary despite the complexity of care and the stress to families.
Previous
Next

Inpatient & Outpatient Medications

  • Patients with leukocyte adhesion deficiency I are at risk for fungal infections with Candida species because of their frequent need for broad-spectrum antibiotics.
Previous
Next

Transfer

  • Most clinical immunologists strongly believe that the great complexity of medical problems for any primary immunodeficiency disease requires the patient to be managed by an immunologist.
  • The subtle signs of infection, the need to offer stem cell transplantation, and the early deaths in patients with leukocyte adhesion deficiency I that is not properly treated suggest that frequent monitoring by a clinical immunologist is essential.
  • The major services for transfer are the intensive care and surgical teams.
Previous
Next

Deterrence/Prevention

  • Prenatal diagnosis for leukocyte adhesion deficiency I is possible by chorionic villus sampling or amniocentesis using DNA methodology in families where the exact mutations have been established. Fetal blood sampling and fluorocytometric testing for the presence of CD18 on lymphocytes, monocytes, and neutrophils can establish the diagnosis when DNA analysis is not available.
  • In leukocyte adhesion deficiency II, ultrasonography for growth retardation, skeletal abnormalities, and distinctive facial features can establish the diagnosis prenatally in some families.
Previous
Next

Complications

  • Patients with leukocyte adhesion deficiency I are at risk for graft versus host disease post–stem cell reconstitution, although graft versus host disease has been less common than in other transplantation settings.
  • Patients with leukocyte adhesion deficiency II experience growth failure and mental retardation, although they are less likely to die of infection. Reports of these patients are so rare that other complications may not be observed adequately yet.
Previous
Next

Prognosis

  • Without hematopoietic stem cell transplantation (HSCT), patients with leukocyte adhesion deficiency I who have an absence of CD18 expression usually die from infection within 2 years of life. The published experience with hematopoietic stem cell transplantation has been excellent with complete immunologic reconstitution. Earlier reviews of leukocyte adhesion deficiency I indicated that unreconstituted patients most often succumbed to bacterial infections. In the author's experience, early recognition and aggressive therapy of bacterial and fungal infections is usually successful. In contrast, no specific therapy is available for the crouplike infections of suspected viral etiology or for aseptic meningitis.
  • Patients with leukocyte adhesion deficiency II show severe developmental delay, which has not been significantly prevented even when fucose replacement seemed to decrease infections and improve phagocytic functions.
Previous
Next

Patient Education

  • The inability to easily detect infection is extremely stressful to families. Aggressive and complicated antibiotic and surgical care may be required for prolonged periods in the home setting, adding further stress.
  • Adequate informed consent for stem cell reconstitution must review the high risk for life-threatening infection during the preparative myeloablative regimen in addition to the risk for failure to engraft and graft versus host disease. Although successful complete immune reconstitution from bone marrow transplantation is reported using fully matched related and unrelated donors or haploidentical donors (ie, parents), patients with leukocyte adhesion deficiency I cannot be guaranteed to have benign courses.
  • The Immune Deficiency Foundation (some states have local chapters) is an important resource for education and for support for patients and families with any primary immunodeficiency disease. The current address is as follows: 25 W. Chesapeake Ave, Suite 206
  • Towson, MD 21204
  • Phone number: 877-666-0866
  • The Jeffrey Modell Foundation also provides educational support and raises funds for research. The current address is as follows: 747 3rd Ave
  • New York, NY 10017
  • Phone: 800-JEFF-844
Previous
 
Contributor Information and Disclosures
Author

Stephen J Nervi, MD  Staff Physician, Department of Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Stephen J Nervi, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Monika I Sidor, MD  Resident Physician, Department of Surgery, University of Michigan at Ann Arbor Medical School

Monika I Sidor, MD is a member of the following medical societies: Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Terry W Chin, MD, PhD  Associate Director, Pediatric Allergy/Immunology/Pulmonology, Miller Children's Hospital, Long Beach Memorial Medical Center; Associate Professor, Department of Pediatrics, University of California, Irvine, School of Medicine

Terry W Chin, MD, PhD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Association of Immunologists, American College of Allergy, Asthma and Immunology, American College of Chest Physicians, American Thoracic Society, California Thoracic Society, Clinical Immunology Society, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

David J Valacer, MD  Consulting Staff, Hoffman La Roche Pharmaceuticals

David J Valacer, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American Thoracic Society, and New York Academy of Sciences

Disclosure: Nothing to disclose.

David Pallares, MD  Clinical Assistant Professor, Department of Pediatrics, Division of Allergy and Immunology, University of Louisville School of Medicine

David Pallares, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD  Associate Professor, Division of Pulmonary, Allergy/Immunology, and Infectious Diseases, Department of Pediatrics, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Mucosal Immunology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. [Guideline] Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. May 2005;94(5 Suppl 1):S1-63. [Medline].

  2. Hanna S, Etzioni A. Leukocyte adhesion deficiencies. Ann N Y Acad Sci. Feb 2012;1250(1):50-5. [Medline].

  3. Anderson DC, Schmalsteig FC, Finegold MJ, et al. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis. Oct 1985;152(4):668-89. [Medline].

  4. Helmus Y, Denecke J, Yakubenia S, et al. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood. Feb 2 2006;[Medline].

  5. Alon R, Etzioni A. LAD-III, a novel group of leukocyte integrin activation deficiencies. Trends Immunol. Oct 2003;24(10):561-6. [Medline].

  6. Kinashi T, Aker M, Sokolovsky-Eisenberg M, et al. LAD-III, a leukocyte adhesion deficiency syndrome associated with defective Rap1 activation and impaired stabilization of integrin bonds. Blood. Feb 1 2004;103(3):1033-6. [Medline]. [Full Text].

  7. McDowall A, Svensson L, Stanley P, Patzak I, Chakravarty P, Howarth K, et al. Two mutations in the KINDLIN3 gene of a new leukocyte adhesion deficiency III patient reveal distinct effects on leukocyte function in vitro. Blood. Jun 10 2010;115(23):4834-42. [Medline].

  8. Lorusso F, Kong D, Jalil AK, et al. Preimplantation genetic diagnosis of leukocyte adhesion deficiency type I. Fertil Steril. Feb 2006;85(2):494.e15-8. [Medline].

  9. Elhasid R, Rowe JM. Hematopoetic Stem Cell Transplantation in Neutrophil Disorders: Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency and Chronic Granulomatous Disease. Clin Rev Allergy Immunol. May 19 2009;[Medline].

  10. Alon R, Aker M, Feigelson S, et al. A novel genetic leukocyte adhesion deficiency in subsecond triggering of integrin avidity by endothelial chemokines results in impaired leukocyte arrest on vascular endothelium under shear flow. Blood. Jun 1 2003;101(11):4437-45. [Medline]. [Full Text].

  11. Bauer TR Jr, Hickstein DD. Gene therapy for leukocyte adhesion deficiency. Curr Opin Mol Ther. Aug 2000;2(4):383-8. [Medline].

  12. Bauer TR, Gu YC, Tuschong LM, et al. Nonmyeloablative hematopoietic stem cell transplantation corrects the disease phenotype in the canine model of leukocyte adhesion deficiency. Exp Hematol. Jun 2005;33(6):706-12. [Medline].

  13. Bunting M, Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol. Jan 2002;9(1):30-5. [Medline].

  14. DeLisser HM, Christofidou-Solomidou M, Sun J, et al. Loss of endothelial surface expression of E-selectin in a patient with recurrent infections. Blood. Aug 1 1999;94(3):884-94. [Medline].

  15. Eklund EA, Freeze HH. The congenital disorders of glycosylation: a multifaceted group of syndromes. NeuroRx. Apr 2006;3(2):254-63. [Medline].

  16. Etzioni A. Leukocyte adhesion deficiencies: molecular basis, clinical findings, and therapeutic options. Adv Exp Med Biol. 2007;601:51-60. [Medline].

  17. Etzioni A, Doerschuk CM, Harlan JM. Of man and mouse: leukocyte and endothelial adhesion molecule deficiencies. Blood. Nov 15 1999;94(10):3281-8. [Medline]. [Full Text].

  18. Etzioni A, Frydman M, Pollack S, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med. Dec 17 1992;327(25):1789-92. [Medline].

  19. Etzioni A, Harlan JM. Cell adhesion and leukocyte adhesion defects. In: Ochs HD, Puck JM, Smith CI, eds. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. Oxford University Press Inc; 1998:375-88.

  20. Etzioni A, Sturla L, Antonellis A, et al. Leukocyte adhesion deficiency (LAD) type II/carbohydrate deficient glycoprotein (CDG) IIc founder effect and genotype/phenotype correlation. Am J Med Genet. Jun 15 2002;110(2):131-5. [Medline].

  21. Etzioni A, Tonetti M. Fucose supplementation in leukocyte adhesion deficiency type II. Blood. Jun 1 2000;95(11):3641-3. [Medline]. [Full Text].

  22. Farinha NJ, Duval M, Wagner E, et al. Unrelated bone marrow transplantation for leukocyte adhesion deficiency. Bone Marrow Transplant. Dec 2002;30(12):979-81. [Medline].

  23. Fiorini M, Vermi W, Facchetti F, et al. Defective migration of monocyte-derived dendritic cells in LAD-1 immunodeficiency. J Leukoc Biol. Oct 2002;72(4):650-6. [Medline].

  24. Gu YC, Bauer TR Jr, Ackermann MR, et al. The genetic immunodeficiency disease, leukocyte adhesion deficiency, in humans, dogs, cattle, and mice. Comp Med. Aug 2004;54(4):363-72. [Medline].

  25. Harris ES, Shigeoka AO, Li W, et al. A novel syndrome of variant leukocyte adhesion deficiency involving defects in adhesion mediated by beta1 and beta2 integrins. Blood. Feb 1 2001;97(3):767-76. [Medline]. [Full Text].

  26. Hidalgo A, Ma S, Peired AJ, Weiss LA, et al. Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood. Mar 1 2003;101(5):1705-12. [Medline]. [Full Text].

  27. Hixson P, Smith CW, Shurin SB, Tosi MF. Unique CD18 mutations involving a deletion in the extracellular stalk region and a major truncation of the cytoplasmic domain in a patient with leukocyte adhesion deficiency type 1. Blood. Feb 1 2004;103(3):1105-13. [Medline]. [Full Text].

  28. Hogg N, Stewart MP, Scarth SL, et al. A novel leukocyte adhesion deficiency caused by expressed but nonfunctional beta2 integrins Mac-1 and LFA-1. J Clin Invest. Jan 1999;103(1):97-106. [Medline].

  29. Kurkchubasche AG, Panepinto JA, Tracy TF Jr, et al. Clinical features of a human Rac2 mutation: a complex neutrophil dysfunction disease. J Pediatr. Jul 2001;139(1):141-7. [Medline].

  30. Luhn K, Wild MK, Eckhardt M, Gerardy-Schahn R, Vestweber D. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nat Genet. May 2001;28(1):69-72. [Medline].

  31. Malawista SE, de Boisfleury Chevance A, et al. Chemotaxis of non-compressed blood polymorphonuclear leukocytes from an adolescent with severe leukocyte adhesion deficiency. Am J Hematol. Jun 2003;73(2):115-20. [Medline].

  32. Mancias C, Infante AJ, Kamani NR. Matched unrelated donor bone marrow transplantation in leukocyte adhesion deficiency. Bone Marrow Transplant. Dec 1999;24(11):1261-3. [Medline].

  33. Marquardt T, Brune T, Luhn K, et al. Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J Pediatr. Jun 1999;134(6):681-8. [Medline].

  34. Marquardt T, Luhn K, Srikrishna G, et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. Dec 15 1999;94(12):3976-85. [Medline].

  35. McDowall A, Inwald D, Leitinger B, et al. A novel form of integrin dysfunction involving beta1, beta2, and beta3 integrins. J Clin Invest. Jan 2003;111(1):51-60. [Medline]. [Full Text].

  36. Pasvolsky R, Feigelson SW, Kilic SS, et al. A LAD-III syndrome is associated with defective expression of the Rap-1 activator CalDAG-GEFI in lymphocytes, neutrophils, and platelets. J Exp Med. Jul 9 2007;204(7):1571-82. [Medline].

  37. Roos D, Meischl C, de Boer M, et al. Genetic analysis of patients with leukocyte adhesion deficiency: genomic sequencing reveals otherwise undetectable mutations. Exp Hematol. Mar 2002;30(3):252-61. [Medline].

  38. Shaw JM, Al-Shamkhani A, Boxer LA, et al. Characterization of four CD18 mutants in leucocyte adhesion deficient (LAD) patients with differential capacities to support expression and function of the CD11/CD18 integrins LFA-1, Mac-1 and p150,95. Clin Exp Immunol. Nov 2001;126(2):311-8. [Medline].

  39. Sturla L, Fruscione F, Noda K, et al. Core fucosylation of N-linked glycans in leukocyte adhesion deficiency/congenital disorder of glycosylation IIc fibroblasts. Glycobiology. Oct 2005;15(10):924-34. [Medline].

  40. Sturla L, Rampal R, Haltiwanger RS, et al. Differential terminal fucosylation of N-linked glycans versus protein O-fucosylation in leukocyte adhesion deficiency type II (CDG IIc). J Biol Chem. Jul 18 2003;278(29):26727-33. [Medline]. [Full Text].

  41. Uzel G, Kleiner DE, Kuhns DB, Holland SM. Dysfunctional LAD-1 neutrophils and colitis. Gastroenterology. Oct 2001;121(4):958-64. [Medline].

  42. Uzel G, Tng E, Rosenzweig SD, Hsu AP, Shaw JM, Horwitz ME. Reversion mutations in patients with leukocyte adhesion deficiency type I (LAD-I). Blood. Sep 17 2007;[Medline].

  43. Wild MK, Luhn K, Marquardt T, Vestweber D. Leukocyte adhesion deficiency II: therapy and genetic defect. Cells Tissues Organs. 2002;172(3):161-73. [Medline].

 
Previous
Next
 
Labial ulceration from which Escherichia coli was cultured in an 8-month-old girl with leukocyte adhesion deficiency type 1 (LAD I). Note the thin bluish scar at the superior aspect of the labia from an earlier cellulitis.
This 3-year-old girl had leukocyte adhesion deficiency type I (LAD I) with complete absence of CD18 expression. Note the typical gingivostomatitis, which was culture-negative for any pathogen.
This 10-month-old patient with severe leukocyte adhesion deficiency type I (LAD I) developed a cervical adenitis caused by Klebsiella pneumoniae. Following incision and drainage, wound healing took 4 months.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.